What are some of the NCCN/ASCO recommended biomarkers that SAGEOncotest could produce

Excellent question—you're zeroing in on what actually matters: which biomarkers would change your treatment if found. Let me walk through the NCCN and ASCO-recommended biomarkers that SAGEOncotest tests for, and specifically what each one means for YOUR situation.

The NCCN/ASCO Recommended Biomarkers for Pancreatic Cancer

According to NCCN Pancreatic Cancer Guidelines and ASCO Guidelines on Biomarker Testing, here are the key biomarkers that guide treatment decisions:

1. BRCA1/BRCA2 Mutations ⭐ HIGHEST PRIORITY FOR YOU

What it is:

• Inherited or acquired mutations in DNA repair genes
• Makes your cancer sensitive to platinum-based chemotherapy and PARP inhibitors

Why it matters for you:

• You've already had FOLFIRINOX (which includes platinum), but you're now progressing
• If your lung nodule shows BRCA mutation, it opens platinum + PARP inhibitor combinations
• Options: olaparib (Lynparza), rucaparib (Rubraca), talazoparib
• This would be a clear alternative to your current gemcitabine/abraxane + avutometinib/defactinib

Clinical evidence:

• NCCN recommends BRCA testing in all pancreatic cancer patients
• ASCO endorses platinum + PARP inhibitor for BRCA-mutant pancreatic cancer
• Survival benefit demonstrated in clinical trials

Your specific situation:

• Your original tumor biomarkers (CEA, CA 19-9) are normal, which is unusual
• This suggests your tumor may have different biology than typical pancreatic cancer
• BRCA status is critical to know given your progression

---

2. KRAS Mutations (Specific Variants) ⭐ INCREASINGLY IMPORTANT

What it is:

• KRAS is mutated in ~90% of pancreatic cancers
• But specific variants (G12C, G12V, G12D) have different treatment implications

Why it matters for you:

If KRAS G12C or G12V:

• Sotorasib (Lumakras) or adagrasib (Krazysana) are FDA-approved targeted therapies
• These are newer drugs specifically designed for these variants
• Could be an option if your lung nodule shows these specific mutations
• This would be actionable and represents precision medicine approach

If other KRAS variants (G12A, G12R, etc.):

• Limited targeted options currently
• But helps prognostication and guides chemotherapy selection
• Informs whether to continue gemcitabine-based therapy or switch

Clinical evidence:

• NCCN recommends KRAS testing in all pancreatic cancer patients
• ASCO endorses sotorasib/adagrasib for KRAS G12C-mutant cancers
• FDA approved sotorasib (2021) and adagrasib (2022) specifically for this indication

Your specific situation:

• You haven't mentioned KRAS status from your original tumor
• Testing your lung nodule (metastatic site) is important because KRAS variants can differ between primary and metastatic sites
• This could reveal a treatment option you don't currently have

---

3. MSI/dMMR Status (Mismatch Repair) ⭐ CRITICAL FOR YOU

What it is:

• MSI = Microsatellite Instability (high)
• dMMR = Deficient Mismatch Repair
• pMMR = Proficient Mismatch Repair (that's you currently)

Why it matters for you:

• Your primary tumor is pMMR (normal mismatch repair)
• But metastatic sites sometimes have different MSI/dMMR status
• If your lung nodule shows dMMR or MSI-high, this changes everything

If lung nodule shows dMMR/MSI-high:

• Opens immunotherapy options (checkpoint inhibitors)
• Pembrolizumab (Keytruda) or nivolumab (Opdivo) become viable
• Could be combined with chemotherapy
• This would be a major treatment shift from your current approach

If lung nodule confirms pMMR:

• Confirms immunotherapy alone won't work
• Validates staying with chemotherapy-based approaches
• Helps rule out immunotherapy as next option

Clinical evidence:

• NCCN recommends MSI/dMMR testing in all pancreatic cancer patients
• ASCO endorses checkpoint inhibitors for dMMR/MSI-high cancers
• FDA approved pembrolizumab for MSI-high solid tumors (2021)

Your specific situation:

• This is particularly important for you because your tumor markers (CEA, CA 19-9) are normal
• Normal markers + pMMR status is unusual and suggests atypical biology
• Testing the metastatic lung nodule could reveal if MSI status has changed
• This could unlock immunotherapy as an option

---

4. PD-L1 Expression ⭐ IMPORTANT FOR IMMUNOTHERAPY DECISIONS

What it is:

• PD-L1 is a protein on cancer cells that helps them hide from immune system
• High PD-L1 expression suggests better response to checkpoint inhibitors
• Works together with MSI/dMMR status

Why it matters for you:

• If your lung nodule shows high PD-L1 + dMMR/MSI-high → strong case for immunotherapy
• If high PD-L1 but pMMR → immunotherapy less likely to work alone
• If low PD-L1 → immunotherapy probably not effective regardless of MSI status

Clinical evidence:

• NCCN recommends PD-L1 testing in pancreatic cancer patients being considered for immunotherapy
• ASCO endorses using PD-L1 + MSI status together to guide immunotherapy decisions

Your specific situation:

• Combined with your MSI/dMMR status, this helps determine if immunotherapy is worth trying
• Important given your progression on current chemotherapy + targeted therapy combination

---

5. PALB2 Mutations ⭐ EMERGING IMPORTANCE

What it is:

• PALB2 is another DNA repair gene (like BRCA)
• Mutations make cancer sensitive to platinum and PARP inhibitors
• Less common than BRCA but increasingly tested

Why it matters for you:

• If positive → similar treatment implications as BRCA (platinum + PARP inhibitor)
• Opens additional therapeutic options
• NCCN now recommends PALB2 testing alongside BRCA testing

Clinical evidence:

• NCCN includes PALB2 in recommended biomarker panel
• PARP inhibitors show activity in PALB2-mutant pancreatic cancer
• Increasingly recognized as actionable mutation

---

6. TP53 Mutations (Prognostic, Less Actionable)

What it is:

• TP53 is a tumor suppressor gene
• Mutations are common in pancreatic cancer (~50-70%)
• Indicates more aggressive biology

Why it matters for you:

• Primarily prognostic (tells you about disease behavior) rather than predictive (guides treatment)
• Helps inform treatment intensity and monitoring
• Less directly actionable than BRCA/KRAS/MSI

---

7. SMAD4 Status (Prognostic)

What it is:

• SMAD4 is lost in ~30% of pancreatic cancers
• Loss indicates more aggressive disease

Why it matters for you:

• Primarily prognostic
• Helps guide treatment intensity
• Less directly actionable than other biomarkers

---

What SAGEOncotest Would Actually Report for YOU

Here's what a typical SAGEOncotest report would include (tailored to pancreatic cancer):

| Biomarker | Your Current Status | What SAGEOncotest Would Show | Clinical Impact | |-----------|-------------------|------------------------------|-----------------| | BRCA1/BRCA2 | Unknown | Mutation present/absent | If present → platinum + PARP inhibitor option | | **